Skip to main content
. 2022 Jul 8;9:869535. doi: 10.3389/fmed.2022.869535

TABLE 5.

Results of scenario-analysis.

Total cost QALY Incremental costs QALYs gained ICER
Non-preemptive DDKT 180,338.83 13.65
Non-preemptive LRKT 187,333.70 14.12 6994.87 0.47 14,944.42

DDKT, deceased-donor kidney transplantation; LRKT, living-related kidney transplantation; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.